Entellus Medical raises $30 million
This article was originally published in The Gray Sheet
Executive Summary
Expanded commercialization of the firm's FinESS endoscopic device for less invasive treatment of chronic sinusitis will be facilitated by a recently completed $30 million "Series D" financing round, announced Nov. 17. A portion of the funds will go toward expanded sales and customer support teams. The Minneapolis firm launched the 510(k)-cleared device in September 2008, and says it is now preparing for nationwide availability in 2010, as well as for overseas marketing. The funding was led by Essex Woodlands Health Ventures
You may also be interested in...
Ethicon Opens Up To Chronic Sinusitis Market With $785 Mil. Acclarent Buy
Johnson & Johnson/Ethicon will use its $785 million acquisition of Acclarent, developer of the Balloon Sinuplasty system for chronic sinusitis, as a platform for growth in the ear, nose and throat business
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.